TY - JOUR
T1 - Prevalence of comorbidities and concomitant medication use in acromegaly
T2 - analysis of real-world data from the United States
AU - Fleseriu, Maria
AU - Barkan, Ariel
AU - del Pilar Schneider, Maria
AU - Darhi, Yannis
AU - de Pierrefeu, Amicie
AU - Ribeiro-Oliveira, Antonio
AU - Petersenn, Stephan
AU - Neggers, Sebastian
AU - Melmed, Shlomo
N1 - © 2021. The Author(s).
PY - 2022/1
Y1 - 2022/1
N2 - PURPOSE: Patients receiving treatment for acromegaly often experience significant associated comorbidities for which they are prescribed additional medications. We aimed to determine the real-world prevalence of comorbidities and concomitant medications in patients with acromegaly, and to investigate the association between frequency of comorbidities and number of concomitantly prescribed medications.METHODS: Administrative claims data were obtained from the IBM® MarketScan® database for a cohort of patients with acromegaly, identified by relevant diagnosis codes and acromegaly treatments, and a matched control cohort of patients without acromegaly from January 2010 through April 2020. Comorbidities were identified based on relevant claims and assessed for both cohorts.RESULTS: Overall, 1175 patients with acromegaly and 5875 matched patients without acromegaly were included. Patients with acromegaly had significantly more comorbidities and were prescribed concomitant medications more so than patients without acromegaly. In the acromegaly and control cohorts, respectively, 67.6% and 48.4% of patients had cardiovascular disorders, the most prevalent comorbidities, and 89.0% and 68.3% were prescribed > 3 concomitant medications (p < 0.0001). Hypopituitarism and hypothalamic disorders, sleep apnea, malignant neoplasms and cancer, and arthritis and musculoskeletal disorders were also highly prevalent in the acromegaly cohort. A moderate, positive correlation (Spearman correlation coefficient 0.60) was found between number of comorbidities and number of concomitant medications in the acromegaly cohort.CONCLUSION: Compared with patients without acromegaly, patients with acromegaly have significantly more comorbidities and are prescribed significantly more concomitant medications. Physicians should consider the number and type of ongoing medications for individual patients before prescribing additional acromegaly treatments.
AB - PURPOSE: Patients receiving treatment for acromegaly often experience significant associated comorbidities for which they are prescribed additional medications. We aimed to determine the real-world prevalence of comorbidities and concomitant medications in patients with acromegaly, and to investigate the association between frequency of comorbidities and number of concomitantly prescribed medications.METHODS: Administrative claims data were obtained from the IBM® MarketScan® database for a cohort of patients with acromegaly, identified by relevant diagnosis codes and acromegaly treatments, and a matched control cohort of patients without acromegaly from January 2010 through April 2020. Comorbidities were identified based on relevant claims and assessed for both cohorts.RESULTS: Overall, 1175 patients with acromegaly and 5875 matched patients without acromegaly were included. Patients with acromegaly had significantly more comorbidities and were prescribed concomitant medications more so than patients without acromegaly. In the acromegaly and control cohorts, respectively, 67.6% and 48.4% of patients had cardiovascular disorders, the most prevalent comorbidities, and 89.0% and 68.3% were prescribed > 3 concomitant medications (p < 0.0001). Hypopituitarism and hypothalamic disorders, sleep apnea, malignant neoplasms and cancer, and arthritis and musculoskeletal disorders were also highly prevalent in the acromegaly cohort. A moderate, positive correlation (Spearman correlation coefficient 0.60) was found between number of comorbidities and number of concomitant medications in the acromegaly cohort.CONCLUSION: Compared with patients without acromegaly, patients with acromegaly have significantly more comorbidities and are prescribed significantly more concomitant medications. Physicians should consider the number and type of ongoing medications for individual patients before prescribing additional acromegaly treatments.
KW - Acromegaly
KW - Comorbidities
KW - Concomitant medications
KW - Injectable medications
KW - Oral medications
KW - Real-world data
KW - Prevalence
KW - Comorbidity
KW - Humans
KW - Acromegaly/complications
KW - United States/epidemiology
KW - Retrospective Studies
KW - Cohort Studies
KW - Databases, Factual
UR - http://www.scopus.com/inward/record.url?scp=85122035322&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/ec0c3b7c-8779-300d-8814-940a93507f31/
U2 - 10.1007/s11102-021-01198-5
DO - 10.1007/s11102-021-01198-5
M3 - Article
C2 - 34973139
AN - SCOPUS:85122035322
SN - 1386-341X
VL - 25
SP - 296
EP - 307
JO - Pituitary
JF - Pituitary
IS - 2
ER -